D. A. Jabs, R. B. Nussenblatt, and J. T. Rosenbaum, Standardization of uveitis nomenclature (SUN) working group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop, Am. J. Ophthalmol, vol.140, pp.509-516, 2005.

J. E. Thorne, E. Suhler, M. Skup, S. Tari, D. Macaulay et al., Prevalence of noninfectious uveitis in the United States: a claims-based analysis, JAMA Ophthalmol, vol.134, pp.1237-1245, 2016.

E. Minos, R. J. Barry, S. Southworth, A. Folkard, P. I. Murray et al., Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment, Orphanet J. Rare Dis, vol.11, p.61, 2016.

A. Tavallali and L. A. Yannuzzi, Idiopathic multifocal choroiditis, J. Ophthalmic Vis. Res, vol.11, pp.429-432, 2016.

P. Sève, L. Kodjikian, L. Adélaïde, and Y. Jamilloux, Uveitis in adults: what do rheumatologists need to know?, Joint Bone Spine, vol.82, pp.308-314, 2015.

A. D. Dick, J. T. Rosenbaum, H. A. Al-dhibi, R. Belfort, A. P. Brézin et al., Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative, vol.125, pp.757-773, 2018.

S. Touhami, E. Diwo, P. Sève, S. Trad, P. Bielefeld et al., Expert opinion on the use of biological therapy in non-infectious uveitis, Expet Opin. Biol. Ther, vol.19, pp.477-490, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02405446

J. H. Kempen, E. Daniel, S. Gangaputra, K. Dreger, D. A. Jabs et al., Methods for identifying long-term adverse effects of treatment in patients with eye diseases: the systemic immunosuppressive therapy for eye diseases (SITE) cohort study, Ophthalmic Epidemiol, vol.15, pp.47-55, 2008.

S. Gangaputra, C. W. Newcomb, T. L. Liesegang, R. O. Kaçmaz, D. A. Jabs et al., Methotrexate for ocular inflammatory diseases, Ophthalmology, vol.116, pp.2188-2198, 2009.

S. Pasadhika, J. H. Kempen, C. W. Newcomb, T. L. Liesegang, S. S. Pujari et al., Azathioprine for ocular inflammatory diseases, Am. J. Ophthalmol, vol.148, pp.500-509, 2009.

E. Daniel, J. E. Thorne, C. W. Newcomb, S. S. Pujari, R. O. Kaçmaz et al., Mycophenolate mofetil for ocular inflammation, Am. J. Ophthalmol, vol.149, pp.423-432, 2010.

G. J. Jaffe, A. D. Dick, A. P. Brézin, Q. D. Nguyen, J. E. Thorne et al., Adalimumab in patients with active noninfectious uveitis, N. Engl. J. Med, vol.375, pp.932-943, 2016.
URL : https://hal.archives-ouvertes.fr/hal-02741384

Q. D. Nguyen, P. T. Merrill, G. J. Jaffe, A. D. Dick, S. K. Kurup et al., Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial, Lancet, vol.388, pp.1183-1192, 2016.

R. B. Nussenblatt, A. G. Palestine, C. C. Chan, and F. Roberge, Standardization of vitreal inflammatory activity in intermediate and posterior uveitis, Ophthalmology, vol.92, pp.467-471, 1985.

H. Vallet, P. Seve, L. Biard, J. Baptiste-fraison, P. Bielefeld et al., Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network, Arthritis Rheum, vol.68, pp.1522-1530, 2016.

J. N. Martel, E. Esterberg, A. Nagpal, and N. R. Acharya, Infliximab and adalimumab for uveitis, Ocul. Immunol. Inflamm, vol.20, pp.18-26, 2012.

C. Fabiani, A. Vitale, G. Emmi, A. Bitossi, G. Lopalco et al., Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis, Clin. Rheumatol, vol.38, pp.63-70, 2019.

G. Hatemi, R. Christensen, D. Bang, B. Bodaghi, A. F. Celik et al., Update of the EULAR recommendations for the management of Behçet's syndrome, Ann. Rheum. Dis, issue.77, pp.808-818, 2018.

E. B. Suhler, A. Adán, A. P. Brézin, E. Fortin, H. Goto et al., Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: visual III, Ophthalmology, vol.125, pp.1075-1087, 2018.

A. Maleki, H. F. Sahawneh, L. Ma, H. Meese, Y. He et al., Infliximab therapy in patients with noninfectious intermediate uveitis resistant to conventional immunomodulatory therapy, Retina, vol.37, pp.836-843, 2017.

A. Galor, D. A. Jabs, H. A. Leder, S. R. Kedhar, J. P. Dunn et al., Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation, Ophthalmology, vol.115, pp.1826-1832, 2008.

R. Lejoyeux, E. Diwo, H. Vallet, D. Saadoun, S. Tezenas-du-montcel et al., Infliximab and adalimumab in uveitic macular edema, Ocul. Immunol. Inflamm, vol.26, pp.991-996, 2018.

F. Mackensen, E. Jakob, C. Springer, B. C. Dobner, U. Wiehler et al., Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial, Am. J. Ophthalmol, vol.156, pp.478-486, 2013.

M. Díaz-llopis, D. Salom, C. Garcia-de-vicuña, M. Cordero-coma, G. Ortega et al., Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 Patients, vol.119, pp.1575-1581, 2012.

M. Schaap-fogler, R. Amer, R. Friling, E. Priel, and M. Kramer, Anti-TNF-? agents for refractory cystoid macular edema associated with noninfectious uveitis, Graefes Arch. Clin. Exp. Ophthalmol, vol.252, pp.633-640, 2014.

Y. J. Sepah, M. A. Sadiq, D. S. Chu, M. Dacey, R. Gallemore et al., Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with non-infectious uveitis, Am. J. Ophthalmol, vol.183, pp.71-80, 2017.

F. Jafri and A. Sammut, A rare case of suicidal ideation related to adalimumab use, Open Access Rheumatol, vol.10, pp.113-115, 2018.

S. R. Rathinam, M. Babu, R. Thundikandy, A. Kanakath, N. Nardone et al., A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis, Ophthalmology, vol.121, pp.1863-1870, 2014.